Mounjaro and Wegovy represent a seismic shift in how doctors treat obesity and type 2 diabetes. Both drugs work by mimicking glucagon-like peptide-1, or GLP-1, a hormone that regulates appetite and blood sugar levels. When injected weekly, they signal the brain to reduce hunger while slowing stomach emptying, making patients feel fuller longer and eat less overall.
Wegovy, made by Novo Nordisk, targets weight loss specifically. Mounjaro, produced by Eli Lilly, treats type 2 diabetes but produces significant weight loss as a side effect. Both have shown clinical results that dwarf traditional weight-loss medications. Patients often lose 15 to 22 percent of their body weight over 68 weeks of treatment.
The drugs work differently from older appetite suppressants. Rather than flooding the nervous system with stimulants, GLP-1 agonists operate through a more targeted biological pathway. They bind to receptors in the brain and gut, creating a cascade of signals that fundamentally alter how the body processes food.
In the UK, access through the National Health Service remains restricted to patients meeting specific criteria, though private prescriptions are available at substantial cost. Demand has outpaced supply globally, with shortages affecting diabetics and those using the drugs off-label for weight loss.
These medications have sparked debate about pharmaceutical innovation, inequality in healthcare access, and whether obesity should be treated primarily as a medical condition. The cultural impact extends beyond medicine into celebrity endorsements and social media discussion, making GLP-1 drugs some of the most talked-about pharmaceuticals in recent years.